Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less
Tracking The Impact Of Drug Regulatory Actions: Consumer Health Outcomes, Risk-benefit Issues And Policy Framework.
Funder
National Health and Medical Research Council
Funding Amount
$439,324.00
Summary
This study will explore what happens in the community when a medicine is withdrawn from the market or discredited due to safety concerns. It will examine the impacts of two recent cases of medicine withdrawal or serious long-term safety concern, on a large cohort of women with high utilisation rates who were monitored during the time the medicines were discredited. The study will be an important guide to future regulatory, media and provider responses when medicines are discredited.
Centre Of Research Excellence In Medicines And Ageing
Funder
National Health and Medical Research Council
Funding Amount
$2,601,415.00
Summary
Medicines have an important place in health and are commonly used for long periods, sometimes life-long. Using medicines wisely requires a careful balance between benefits and harmful effects. Currently, there is limited information to guide medicines use over a lifetime. Using large linked datasets, the CRE in Medicines and Ageing will generate much needed evidence about real world medicines use to support clinical and pharmaceutical policy decisions.
Alcohol And Other Drug Treatment Funding, Purchasing And Workforce: Empirical Analyses To Inform Policy
Funder
National Health and Medical Research Council
Funding Amount
$473,865.00
Summary
Alcohol and drug treatment works: it improves health and reduces the social impact of alcohol and drug use. The treatment itself is not, however, the only variable that impacts on whether health outcomes are improved. The way in which governments fund, purchase and structure the treatment service system is also important. This study will empirically test the relationship between treatment outcome and the structures that governments put in place, providing new evidence to inform decision-making.
Preventing Anxiety, Depression And Substance Use In Adolescents.
Funder
National Health and Medical Research Council
Funding Amount
$1,709,988.00
Summary
Anxiety, depressive and substance use disorders account for three quarters of the disability attributed to mental disorders. Yet we have few models of well-implemented prevention programs for these common disorders. The current proposal addresses this gap by evaluating an innovative internet-based approach to preventing mental health and substance use problems in Australian adolescents.
Development Of A New High Throughput Screen For Drug Binding To HERG K+ Channels
Funder
National Health and Medical Research Council
Funding Amount
$351,320.00
Summary
Inadvertent drug block of hERG, a potassium channel in the heart, can cause cardiac arrhythmias and sudden cardiac death. Screening for hERG toxicity has become a major hurdle for development of new drugs. We will use a mutant hERG protein that has enhanced drug binding to develop a high throughput test for hERG toxicity. Identification of dangerous drugs early in the drug discovery process will save the pharmaceutical industry millions of dollars in the costs of brining new drugs to market.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Treatment Of Acute Otitis Media (AOM) In Low Risk Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$1,640,326.00
Summary
A randomised clinical trial design will be used to compare two different approaches to the treatment of acute middle ear infections in Aboriginal children living in urban communities: initial observation or immediate antibiotic prescription. The relative acceptability and cost effectiveness of treatment options will be studied. The evidence will allow primary care clinicians to confidently recommend treatment that maximises health benefits and reduces complications such as hearing impairment.
Parental Supply Of Alcohol To Children: Associations With Early Adult Health – “binge” Drinking, Alcohol-related Harms, Aggression, And Alcohol Use Disorders
Funder
National Health and Medical Research Council
Funding Amount
$1,143,477.00
Summary
We will investigate of the impacts of parental supply of alcohol between 13-18 years, on early adult alcohol use (19-23 years). We will follow an existing cohort of ~1,810 parent-child dyads, and assess the development of alcohol use, disorders, harms and aggression. We will investigate the impacts of: parental supply of sips vs drinks; supervised vs unsupervised supply; and modifying effects of contexts of supply and mediators (such as peer, child factors, etc.) controlling for confounders.
Randomised Double-blind Placebo-controlled Study Of Lisdexamfetamine For The Treatment Of Methamphetamine Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,303,735.00
Summary
Addiction to methamphetamines (‘ice’) is a growing community problem linked to serious disease and death. Current counselling approaches have limited success on their own, and more effective treatments linked to medications are needed. Lisdexamfetamine is a newly licenced stimulant medication with great promise in treating these patients. This trial will examine whether lisdexamfetamine (with counselling) safely reduces methamphetamine use and improves health and wellbeing among heavy users.